

The nephSAP editorial team and the KSAP editorial board extend their sincere appreciation to the following reviewers. Their efforts and insights help improve the quality of these postgraduate education offerings.

nephSAP Review Panel, Volume 21, Number 5, December 2022

Manohar Bairy, MBBS, MD
Tan Tock Seng Hospital
SINGAPORE

Anip Bansal, MD, FASN
University of Colorado Anschutz Medical Campus
UNITED STATES

Khaled Boubes, MD, FASN
The Ohio State University
UNITED STATES

Kiran M. Goli, MD, FASN
Kidney Care Specialists, LLC
UNITED STATES

Elvira O. Gosmanova, MD, FASN
Albany Medical College
UNITED STATES

Insara Jaffer Sathick, MBBS
Memorial Sloan Kettering Cancer Center
UNITED STATES

George Jarad, MD
Washington University School of Medicine
UNITED STATES

Poonum Khalid, IL, MBBS
Nishtar medical university Multan
PAKISTAN

Sana F. Khan, MD
University of Virginia
UNITED STATES

Norbert H. Lameire, MD, PhD
Ghent University
BELGIUM

Amr El-Husseini Mohamed, MD, PhD
University of Kentucky
UNITED STATES

Chanigan Nilubol, MD
MedStar Georgetown University Hospital
UNITED STATES

Arvind Ponnusamy
Royal Preston Hospital
UNITED KINGDOM

Anand M. Ravindran, MD, MBBS
Toledo Clinic Nephrology
UNITED STATES

Muhammad Abdur Razzak, MD, MBBS
Dhaka Medical College
BANGLADESH

Iqbal Hamid Shah, MD, MBBS
King Saud University Medical City
SAUDI ARABIA

Amit Sharma, MD, MBBS, FASN
FORTIS HOSPITAL
INDIA

Michiko Shimada, MD, PhD, FASN
Hirosaki University
JAPAN

Jun Shoji, MD
University of California, San Francisco
UNITED STATES

Nicole S. Stankus, MD, MS, FASN
University of Chicago
UNITED STATES

Anna T. Valson, MD
Christian Medical College
INDIA

Suthaharan Vimalendran, MD
Orillia Soldiers Memorial Hospital
CANADA

Eranga Wijewickrama, MD, PhD, FASN
University of Colombo
SRI LANKA

Learning Objectives

1. To recognize the importance of clinical, laboratory, and morphologic manifestations of glomerular diseases of the kidneys to enhance skills in diagnostic and prognostic evaluation of these disorders.
2. To discuss and interpret the potential pathogenetic mechanisms that underlie primary and secondary forms of glomerular diseases.
3. To describe the rationale, efficacy, and safety of current and emerging therapeutic approaches to primary and secondary glomerular diseases of the kidneys.

Target Audience:

Physicians, scientists, advanced practitioners, nurses, pharmacists, and other health professionals working and training in the field of nephrology.

Accreditation Statement



JOINTLY ACCREDITED PROVIDER®
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement – Physicians: The American Society of Nephrology designates this enduring material for a maximum of 10.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to Joint Accreditation for the purpose of granting ABIM MOC credit.

MOC points will be applied to only those ABIM candidates who have enrolled in the MOC program. It is your responsibility to complete the ABIM MOC enrollment process.

Original Release Date

December 2022

CME/MOC Termination Date

November 30, 2024 at 11:59 pm ET

Examination Available Online

On or before December 29, 2022

Estimated Time for Completion

10 hours

Self-Assessment Examination

- ▶ Answers with explanations are provided with a passing score after the first and/or second attempt.
- ▶ This issue will be archived on December 1, 2024, and answers with explanations will be posted on the ASN website.

Method of Participation

- ▶ Read the entire issue that is supplemented by original articles in the reference lists.
- ▶ Complete the online self-assessment examination.
- ▶ Each participant is allowed **two attempts** to pass the examination (75% correct) for CME and MOC.
- ▶ Upon completion, review your score and incorrect answers and print your certificate.

Activity Evaluation, CE, and MOC

1. Go to the **ASN eLEARNING CENTER** (education.asn-online.org)
2. Select **MY ACTIVITIES** from the left-hand navigation.
3. Select the corresponding issue.
4. Read all information on the Overview screen.
5. Follow the onscreen instructions to:
 - a. Complete the Exam (*i.e.*, post test),
 - b. Complete the Evaluation,
 - c. Claim credit/MOC
 - i. **IMPORTANT**: select the **credit type** that **corresponds with your designation**, and
 - d. Print a Certificate

Your ASN Transcript is available on the **ASN website**

- ▶ Go to the ASN website and log in to your ASN Profile page: <https://www.asn-online.org/myasn/profile.aspx>
- ▶ Select the **CME/CE** Transcript tab
- ▶ View credits claimed or print a certificate with continuing education information for completed learning activities

System Requirements

Compatible Browser and Software

The nephSAP website (nephsap.org) is formatted for cross-browser functionality and should display correctly in all currently supported web browsers. Individual nephSAP articles are available as dynamic HTML or in Portable Document Format (PDF), which requires Adobe Reader or comparable PDF viewing software.

Monitor Settings

The nephSAP website was designed to be viewed in a 1024 × 768 or higher resolution.

Medium or Combination of Media Used

The media used include content provided online as dynamic HTML or downloadable PDF, in addition to an online evaluation and self-assessment examination.

Technical Support

If you have difficulty viewing any of the pages, please refer to the nephSAP technical support page for possible solutions. If you continue having problems, contact ASN at nephsap@asn-online.org.

ASN Disclosure Policy

It is the policy of American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN's educational activities are expected to disclose all their and their life spouse/partner's financial relationships with "ineligible companies" within the prior 24 months as well as other non-financial interests. ("Ineligible companies" are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.) Participants should note that the use of products outside US Food and Drug Administration (FDA) approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications.

The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in educational activities, but rather to ensure that these activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for this activity to complete disclosure forms on the ASN website. Responses are listed below.

Disclosures have been reviewed and assessed by ASN. All relationships with ineligible companies have been identified and all relevant financial relationships have been mitigated.

EDITORS:

Alice M. Sheridan, MD—*Employer(s)*: Brigham and Women's Hospital; No additional relevant financial relationship(s) with ineligible companies to disclose.

Martina M. McGrath, MChB, FASN—*Employer(s)*: Brigham and Women's Hospital; VA Boston Medical Center; No additional relevant financial relationship(s) with ineligible companies to disclose.

EDITORIAL AUTHOR:

Ali G. Gharavi, MD—*Employer(s)*: Columbia University; *Consultancy*: Astra Zeneca Center for genomics research, Goldfinch Bio; Actio biosciences, Novartis; *Ownership Interest*: Actio biosciences; *Research Funding*: Renal Research Institute, Natera; *Honoraria*: Sanofi, Alnylam; *Advisory or Leadership Role*: Editorial board: JASN and Journal of Nephrology.

Emily E. Groopman, MD, PhD—*Employer(s)*: Columbia University; No other financial relationships with ineligible companies to disclose.

AUTHORS:

Woojin Ahn, MD, PhD—*Employer(s)*: Skidmore, Owings & Merrill; *Patents or Royalties*: Wolters Kluwer

Fernando C. Fervenza, MD, PhD, FASN—*Employer(s)*: Mayo Clinic; *Consultancy*: Alexion Pharmaceuticals, ByoCrystal, Takeda, Novartis, Galapagos, GSK, Otsuka; *Research Funding*: Genentech, Hoffman La Roche, Janssen Pharmaceutical, Chemocentryx, Retrophin, Morphosys; *Honoraria*: UpToDate; *Advisory or Leadership Role*: UpToDate, Kidney International, Nephrology, Nephrology Dialysis and Transplantation, Journal of the American Society of Nephrology

Stephen P. McAdoo, MA, MBBS, PhD—*Employer(s)*: Imperial College London; *Consultancy*: GSK, Vifor; *Research Funding*: Therini Bio; *Honoraria*: Rigel Pharmaceuticals, ThermoFisher Scientific, Celltrion; *Advisory or Leadership Role*: Co-chair United Kingdom & Ireland Vasculitis Society (unpaid)

Amy K. Mottl, MD, MPH, FASN—*Employer(s)*: University of North Carolina at Chapel Hill; *Consultancy*: Bayer, Chinook; *Research Funding*: Alexion, Aurinia, Bayer, Calliditas, Duke Clinical Research Institute, Pfizer, University of Pennsylvania; *Honoraria*: Bayer, UpToDate; *Advisory or Leadership Role*: Bayer, Chinook

Susanne B. Nicholas, MD, PhD, MPH—*Employer(s)*: David Geffen School of Medicine at UCLA; *Consultancy*: Janssen Pharmaceutical, Inc., Bayer, Goldfinch, Inc., Travere Pharmaceutical, GeorgeClinical, Boehringer Ingelheim Pharmaceutical, AstraZeneca, Terasaki Biomedical Innovation., NovoNordisk; *Research Funding*: Bayer, Goldfinch, Inc., Travere, Terasaki Institute of Biomedical Innovation; *Honoraria*: Janssen Pharmaceutical, Inc., Bayer, George Clinical, Boehringer Ingelheim/Lilly Pharmaceutical, AstraZeneca, NovoNordisk; *Patents or Royalties*: UCLA; *Advisory or Leadership Role*: Volunteer: President of the National Kidney Foundation of Southern California and Southern Nevada Medical Advisory, Board Executive Committee: Board of Directors, President-Elect Women of Nephrology, Paid: Janssen Pharmaceutical, Boehringer Ingelheim/Lilly Pharmaceutical, Bayer, NovoNordisk, AstraZeneca, Janssen; *Speakers Bureau*: Janssen Pharmaceutical; Bayer; Boehringer Ingelheim Pharmaceutical; Astra Zeneca

Charles D. Pusey, MD, FASN—*Employer(s)*: Imperial College London; *Consultancy*: Vifor, Alentis; *Honoraria*: Med Update Europe, Amgen; *Advisory or Leadership Role*: Clinical Journal of the American Society of Nephrology

Meghan E. Sise, MD, MS—*Employer(s)*: Massachusetts General Hospital; *Consultancy*: Travere, Mallinckrodt, Novartis; *Research Funding*: Gilead Sciences, Abbvie, Merck, EMD-Serono, Angion

Ladan Zand, MD—*Employer(s)*: Mayo Clinic, Rochester, MN; *Research Funding*: Mallinckrodt, Janssen pharmaceuticals, Genentech

ASN STAFF: Suzanne P. Armstrong, MA—*Employer(s)*: American Society of Nephrology; No additional relevant financial relationship(s) with ineligible companies to disclose.

Commercial Support

There is no commercial support for this issue.